Ellis Chu
Director of Finance/CFO chez JHL BIOTECH, INC.
Profil
Ellis Chu is currently working as the Co-Chief Financial Officer & Senior Vice President at WuXi AppTec Co., Ltd.
and as the Chief Financial Officer at Eden Biologics, Inc. He previously worked as a Managing Director at Merrill Lynch (Asia Pacific) Ltd., Director-Asia IBD at Citigroup Global Markets Asia Ltd., Managing Director at Ion Pacific Ltd., and Vice President-Investment Banking at Nomura International (Hong Kong) Ltd.
Mr. Chu completed his undergraduate degree at Northwestern University and earned an MBA from Columbia Business School.
Postes actifs de Ellis Chu
| Sociétés | Poste | Début |
|---|---|---|
| JHL BIOTECH, INC. | Director of Finance/CFO | 01/05/2018 |
| WUXI APPTEC CO., LTD. | Director of Finance/CFO | - |
Anciens postes connus de Ellis Chu
| Sociétés | Poste | Fin |
|---|---|---|
Ion Pacific Ltd.
 Ion Pacific Ltd. Investment ManagersFinance Ion Pacific Ltd (Ion Pacific) is a private equity/venture capital firm founded in 2015 by Itamar Har-Even and Michael Joseph. The firm is headquartered in New York. | Corporate Officer/Principal | - |
Citigroup Global Markets Asia Ltd.
 Citigroup Global Markets Asia Ltd. Investment Banks/BrokersFinance Citigroup Global Markets Asia Ltd. (CGMA) is a securities brokerage firm headquartered Hong Kong. They are a subsidiary of Citigroup Global Markets Hong Kong Holdings Ltd., ultimately owned by Citigroup, Inc. (NYSE: C) in the US. Formerly known as Citi Smith Barney, the firm was reorganized in 2008 when Citigroup combined their brokerage and private banking businesses. CGMA offers stock trading services to various institutional investors. | Corporate Officer/Principal | - |
Merrill Lynch (Asia Pacific) Ltd.
 Merrill Lynch (Asia Pacific) Ltd. Investment ManagersFinance Merrill Lynch (Asia Pacific) Ltd. (Merrill Lynch-Asia Pacific) is the financial management subsidiary of Merrill Lynch HK Services, Ltd., ultimately owned by Bank of America Corp. (NYSE: BAC) in the US. Based in Hong Kong, the firm provides financial management and advisory services. | Corporate Officer/Principal | - |
Nomura International (Hong Kong) Ltd.
 Nomura International (Hong Kong) Ltd. Investment Banks/BrokersFinance Nomura International (Hong Kong) Ltd. (Nomura International HK) is the brokerage subsidiary of Nomura Asia Pacific Holdings Co. Ltd., which is ultimately-owned by Nomura Holdings, Inc. (TYO: 8604) in Japan. Headquartered in Hong Kong, the firm’s global markets team offers research, sales and trading of global securities to a diverse range of clients globally, including institutional investors, financial institutions, corporates, financial sponsors and government entities. Nomura International HK operates a truly integrated, cross-asset platform which includes research, sales and trading in equities, currencies, rates and credit in cash and derivative products. | Corporate Officer/Principal | - |
Formation de Ellis Chu
| Northwestern University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| WUXI APPTEC CO., LTD. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Nomura International (Hong Kong) Ltd.
Nomura International (Hong Kong) Ltd. Investment Banks/BrokersFinance Nomura International (Hong Kong) Ltd. (Nomura International HK) is the brokerage subsidiary of Nomura Asia Pacific Holdings Co. Ltd., which is ultimately-owned by Nomura Holdings, Inc. (TYO: 8604) in Japan. Headquartered in Hong Kong, the firm’s global markets team offers research, sales and trading of global securities to a diverse range of clients globally, including institutional investors, financial institutions, corporates, financial sponsors and government entities. Nomura International HK operates a truly integrated, cross-asset platform which includes research, sales and trading in equities, currencies, rates and credit in cash and derivative products. | Finance |
Merrill Lynch (Asia Pacific) Ltd.
Merrill Lynch (Asia Pacific) Ltd. Investment ManagersFinance Merrill Lynch (Asia Pacific) Ltd. (Merrill Lynch-Asia Pacific) is the financial management subsidiary of Merrill Lynch HK Services, Ltd., ultimately owned by Bank of America Corp. (NYSE: BAC) in the US. Based in Hong Kong, the firm provides financial management and advisory services. | Finance |
Citigroup Global Markets Asia Ltd.
Citigroup Global Markets Asia Ltd. Investment Banks/BrokersFinance Citigroup Global Markets Asia Ltd. (CGMA) is a securities brokerage firm headquartered Hong Kong. They are a subsidiary of Citigroup Global Markets Hong Kong Holdings Ltd., ultimately owned by Citigroup, Inc. (NYSE: C) in the US. Formerly known as Citi Smith Barney, the firm was reorganized in 2008 when Citigroup combined their brokerage and private banking businesses. CGMA offers stock trading services to various institutional investors. | Finance |
Eden Biologics, Inc.
 Eden Biologics, Inc. Pharmaceuticals: MajorHealth Technology Eden Biologics, Inc. is engaged in the manufacture and sale of bio-pharmaceuticals products. It offers cell line cloning, antibody cloning, monoclonal antibody, cell line development, master and working cell banks, cell culture process development, purification process development, formulation development, and analytical assays. The company was founded on June 14, 2012 and is headquartered in Zhupei, Taiwan. | Health Technology |
Ion Pacific Ltd.
Ion Pacific Ltd. Investment ManagersFinance Ion Pacific Ltd (Ion Pacific) is a private equity/venture capital firm founded in 2015 by Itamar Har-Even and Michael Joseph. The firm is headquartered in New York. | Finance |
